Boston (DbTechNo) - GlaxoSmithKline have announced study results that suggest their cervical cancer vaccine Cervarix protects women from numerous types of HPVs.
Currently Merck’s Gardasil is the leading cervical cancer vaccine on the market.
According to Glaxo, their study of more than 18,000 women proved that their vaccine prevented HPV 16 and 18, and also showed the ability to fend off HPV 31, 33 and 45.
The women in the study were between 15 and 25 years of age, and received either Cervarix or a hepatitis A vaccine.
Those women who received all 3 shots of Cervarix were up to 92% protected from HPVs linked to cervical cancer.
Cervarix has been approved for cervical cancer protection in Europe but not yet in the United States.
Cervical cancer is one of the more lethal forms of the disease, and few women survive it fully.
No comments:
Post a Comment